Ben Boursi1, Kevin Haynes1, Ronac Mamtani1, Yu-Xiao Yang2. 1. Division of Gastroenterology (BB, YXY), Center for Clinical Epidemiology and Biostatistics (BB, KH, RM, YXY), Department of Biostatistics and Epidemiology (BB, KH, RM, YXY), Division of Hematology/Oncology (RM), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Integrated Cancer Prevention Center, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel (BB). 2. Division of Gastroenterology (BB, YXY), Center for Clinical Epidemiology and Biostatistics (BB, KH, RM, YXY), Department of Biostatistics and Epidemiology (BB, KH, RM, YXY), Division of Hematology/Oncology (RM), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Integrated Cancer Prevention Center, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel (BB). yangy@mail.med.upenn.edu.
Abstract
BACKGROUND: Current screening guidelines for colorectal cancer (CRC) do not consider thyroid dysfunction as a risk factor for disease development. We sought to determine the risk of developing CRC in patients with thyroid dysfunction, with and without thyroid hormone replacement (THR). METHODS: We conducted a nested case-control study using a large population-based medical records database from the United Kingdom. Study case patients were defined as those with any medical code of CRC. Subjects with familial colorectal cancer syndromes or inflammatory bowel disease (IBD) were excluded. For every case patient, four eligible control patients matched on age, sex, practice site, and duration of follow-up before index date were selected using incidence density sampling. Exposure was THR therapy before index date. We further divided the THR unexposed group into patients with hypothyroidism (TSH > 4 mg/dl), patients with hyperthyroidism (TSH < 0.4 mg/dl), and subjects without documented thyroid abnormality. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for CRC were estimated using conditional logistic regression. All statistical tests were two-sided. RESULTS: We identified 20990 CRC patients and 82054 control patients. The adjusted odds ratio for CRC associated with THR was 0.88 (95% CI = 0.79 to 0.99, P = .03) and 0.68 (95% CI = 0.55 to 0.83, P < .001) for treatment initiated five to 10 years and more than 10 years before index date, respectively. This protective association increased with cumulative duration of therapy. In contrast, hyperthyroidism (adjusted OR = 1.21, 95% CI = 1.08 to 1.36, P = .001) or untreated hypothyroidism (adjusted OR = 1.16, 95% CI = 1.08 to 1.24, P < .001) were associated with increased risk of CRC. CONCLUSION: Long-term THR is associated with a decreased risk of CRC. Hyperthyroidism and untreated hypothyroidism are associated with modestly elevated risk of CRC.
BACKGROUND: Current screening guidelines for colorectal cancer (CRC) do not consider thyroid dysfunction as a risk factor for disease development. We sought to determine the risk of developing CRC in patients with thyroid dysfunction, with and without thyroid hormone replacement (THR). METHODS: We conducted a nested case-control study using a large population-based medical records database from the United Kingdom. Study case patients were defined as those with any medical code of CRC. Subjects with familial colorectal cancer syndromes or inflammatory bowel disease (IBD) were excluded. For every case patient, four eligible control patients matched on age, sex, practice site, and duration of follow-up before index date were selected using incidence density sampling. Exposure was THR therapy before index date. We further divided the THR unexposed group into patients with hypothyroidism (TSH > 4 mg/dl), patients with hyperthyroidism (TSH < 0.4 mg/dl), and subjects without documented thyroid abnormality. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for CRC were estimated using conditional logistic regression. All statistical tests were two-sided. RESULTS: We identified 20990 CRC patients and 82054 control patients. The adjusted odds ratio for CRC associated with THR was 0.88 (95% CI = 0.79 to 0.99, P = .03) and 0.68 (95% CI = 0.55 to 0.83, P < .001) for treatment initiated five to 10 years and more than 10 years before index date, respectively. This protective association increased with cumulative duration of therapy. In contrast, hyperthyroidism (adjusted OR = 1.21, 95% CI = 1.08 to 1.36, P = .001) or untreated hypothyroidism (adjusted OR = 1.16, 95% CI = 1.08 to 1.24, P < .001) were associated with increased risk of CRC. CONCLUSION: Long-term THR is associated with a decreased risk of CRC. Hyperthyroidism and untreated hypothyroidism are associated with modestly elevated risk of CRC.
Authors: James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom Journal: Pharmacoepidemiol Drug Saf Date: 2007-04 Impact factor: 2.890
Authors: Johannes L P Kuijpens; Ivan Nyklíctek; Marieke W J Louwman; Tony A P Weetman; Victor J M Pop; Jan-Willem W Coebergh Journal: Thyroid Date: 2005-11 Impact factor: 6.568
Authors: Faith B Davis; Shaker A Mousa; Laura O'Connor; Seema Mohamed; Hung-Yun Lin; H James Cao; Paul J Davis Journal: Circ Res Date: 2004-04-29 Impact factor: 17.367
Authors: Michael S Simon; Rowan T Chlebowski; Jean Wactawski-Wende; Karen C Johnson; Andrew Muskovitz; Ikuko Kato; Alicia Young; F Allan Hubbell; Ross L Prentice Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Hung-Yun Lin; Mingzeng Sun; Heng-Yuan Tang; Cassie Lin; Mary K Luidens; Shaker A Mousa; Sandra Incerpi; George L Drusano; Faith B Davis; Paul J Davis Journal: Am J Physiol Cell Physiol Date: 2009-01-21 Impact factor: 4.249
Authors: Alf Inge Hellevik; Bjørn Olav Asvold; Trine Bjøro; Pål R Romundstad; Tom Ivar L Nilsen; Lars J Vatten Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01-20 Impact factor: 4.254
Authors: Marta K Powell; Dana Cempirkova; Pavel Dundr; Tereza Grimmichova; Ferdinand Trebicky; Robert E Brown; Jana Gregorova; Martina Litschmannova; Katerina Janurova; Michal Pesta; Petr Heneberg Journal: Transl Oncol Date: 2019-12-30 Impact factor: 4.243
Authors: Shuai Yuan; Siddhartha Kar; Mathew Vithayathil; Paul Carter; Amy M Mason; Stephen Burgess; Susanna C Larsson Journal: Int J Cancer Date: 2020-04-03 Impact factor: 7.316